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A B S T R A C T
Straightforward and effective methods are required for the bioconjugation of proteins to surfaces and
particles. Previously we demonstrated that the fusion of a single domain antibody with the biotin binding
molecule rhizavidin provided a facile method to coat biotin-modiﬁed surfaces with a highly active and
oriented antibody. Here, we constructed similar single domain antibody—rhizavidin fusions as well as
unfused rhizavidin with a His-tag. The unfused rhizavidin produced efﬁciently and its utility for assay
development was demonstrated in surface plasmon resonance experiments. The single domain
antibody-rhizavidin fusions were utilized to coat quantum dots that had been prepared with surface
biotins. Preparation of antibody coated quantum dots by this means was found to be both easy and
effective. The prepared single domain antibody-quantum dot reagent was characterized by surface
plasmon resonance and applied to toxin detection in a ﬂuoroimmunoassay sensing format.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Single domain antibodies (sdAbs), derived from heavy chain
only antibodies found in camelids (i.e. camels, llamas, and alpacas),
often possess high afﬁnity and the ability to refold and bind antigen
after heat denaturation [1–4]. Because these binding elements are
produced recombinantly, they can be tailored through protein
engineering for speciﬁc applications. SdAbs, in general, produce
very well in Escherichia coli; sdAb fusion constructs are also
produced more readily than traditional antibody binding frag-
ments that include both heavy and light chains. For example,
expression of sdAbs as genetic fusions with peptides, or high-
melting temperature proteins is a proven route towards generating
highly stable molecules with enhanced utility [5–10]. Fusions have
been used for a variety of purposes including: providing improved
cytoplasmic production of stable sdAbs, increasing solubility of
sdAbs, as well as providing oriented capture reagents [5,7,11,12].
We recently described the production and characterization of a
genetic fusion between a sdAb and rhizavidin (RZ) [10], a biotin
binding protein (derived from the symbiotic nitrogen-ﬁxing* Corresponding author.
E-mail address: george.anderson@nrl.navy.mil (G.P. Anderson).
http://dx.doi.org/10.1016/j.btre.2016.03.001
2215-017X/Published by Elsevier B.V. This is an open access article under the CC BY-Nbacterium Rhizobium etli CFN42) [13]. Unlike streptavidin, RZ
putatively forms a homodimer instead of a tetramer [13,14]. RZ has
a melting temperature of over 100 C in the presence of biotin, and
75 C in its absence. The sdAb-RZ fusion provided the same
desirable characteristics, such as providing oriented capture, as
fusions with the streptavidin core protein [11]. Importantly,
protein production was improved by approximately 20-fold
compared to the sdAb-streptavidin core fusion [10].
Luminescent quantum dots (QDs) provide robust ﬂuorophores
that have been incorporated for applications including biosensing
and imaging [15,16]. Conjugates of sdAbs with QDs, which couple
stable recognition elements with robust ﬂuorophores, have been
described for detection, imaging and diagnostic applications
[17–23]. Several methods for bioconjugation of proteins to QDs
have been described; for instance, we have previously utilized
directional conjugation of sdAbs to QDs through an extended poly
histidine tail [17,20,24]. One of the previous generation of sdAb-QD
reagents we tested was based on QDs made water compatible
through capping with dihydrolipoic acid (DHLA). QDs functional-
ized with DHLA-PEG based-ligands are not as amenable to
conjugation through an extended histidine tail, however they
offer functionality and stability over a wider pH range [17,25]. An
advantage of sdAbs is their ability to function over a wide range of
conditions [26,27] including intracellular [28]. Therefore it isC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sdAbs to QDs functionalized with DHLA-PEG ligands that provide
an increased biocompatibility. The recent development of
DHLA-PEG capped QDs with a portion of the cap functionalized
with biotin [29,30], in conjunction with fusions of sdAbs with RZ
provides an alternate route for directional conjugates of sdAbs on
QDs. A schematic illustrating both a sdAb-QD conjugate formed
using DHLA-capped QDs with attachment of the sdAb through an
extended histidine tail and a sdAb-QD conjugate utilizing the
DHLA-PEG biotinylated QDs and a sdAb-RZ genetic fusion is shown
in Fig. 1. Having a wide variety of methods to form effective sdAb-
QD conjugates is advantageous as it provides researchers the
ability to choose the conjugation method most appropriate for
their assay or imaging conditions.
This current work focuses on ricin detection. Ricin is a
60–65 kDa highly potent toxin which consists of an A and B
subunit. The A subunit is the enzymatic portion responsible for
ribosome inactivation, while the B subunit binds the cell to
facilitate entry of the toxin [31]. To detect ricin the sdAb, D12f,
which has both high afﬁnity and good thermal stability (Tm = 78
C) [32], was produced as a fusion with RZ. D12f better
complements the high stability of RZ than the original C8 anti-
ricin sdAb used as a fusion partner with RZ, which binds the same
epitope and has a high afﬁnity for ricin, but melts 60 C. In
addition, because we had observed sporadic degradation of
constructs that utilized the llama heavy chain antibody’s upper
hinge as a linker, we switched to a generic10-amino acid Gly-Ser
linker to join D12f to RZ. We also prepared the unfused RZ with a
C-terminal hexa histidine tag (RZh), evaluated its biophysical
characteristics and demonstrated its utility for use as a regenerable
ligand via surface plasmon resonance (SPR) using HTE (6x-His
binding) sensor chips. Nevertheless, the main objective was
demonstrating the utility of the sdAb-RZ fusion by formation of
a bioconjugate between the D12f-RZ and QDs that have biotins
incorporated on a portion of their capping ligands. The orientedFig. 1. Schematic of sdAb-QDs prepared previously, through an extended histidine tail on
The left side shows a DHLA-capped QD onto which sdAb have been conjugated through an
OMe and 20% DHLA-PEG400-biotin onto which sdAb-RZ are conjugated through the R
structure from PBD:3EW2 [14]. The components are not drawn to scale.immobilization provided by the RZ on the QDs yielded a highly
active sdAb that binds target effectively.
2. Materials and methods
2.1. Construction SdAb-RZ fusions with Gly-Ser linker
The D12f-L10-RZ was constructed by ﬁrst inserting the RZ into
the XhoI site of a pET22b expression vector in which the D12f sdAb
sequence had been cloned into NcoI-NotI sites (D12f-pET22b); this
vector includes a C-terminal 6xHis tag [32]. The RZ fragments
ﬂanked with a XhoI site at both ends were ampliﬁed from the
original vector using PCR and inserted to the XhoI site within D12f-
pET22b. D12f-RZ [33] then served as a template to insert a
10 amino acid Gly-Ser linker (L10, GGGGSGGGGS) using the
Quikchange II mutagenesis kit and minor modiﬁcations to the
manufacturer’s protocol (Agilent Technologies; Santa Clara, CA).
Mutagenesis was achieved using the forward primer,
50-GCGGCCGCACTCGAGGGCGGTGGCGG-
TAGCGGCGGTGGCGGTTCTTTTGATGCGTCCAATTTTAAA-30, and its
reverse complement sequence as the reverse primer. In brief, low
annealing temperature (47 C) and 18 ampliﬁcation cycles were
employed and the rest of procedures were unchanged from the
manufacturer’s protocol, to obtain the mutated plasmid. All the
clones were conﬁrmed by sequencing (Euoﬁns Genomics; Hunts-
ville, AL). The mutant protein is termed D12f-L10-RZ. All restriction
enzymes and T4 DNA ligase were purchased from New England
Biolabs, Inc. (Ipswich, MA).
2.2. Construction of unfused RZ with a C-terminal hexa histidine tag
(RZh) in pET22b(+)
The rhizavidin fragment was excised from D12f-RZ using the
restriction enzyme XhoI. Gel puriﬁcation of the excised fragment
was performed with QIAquick Gel Extraction Kit (QIAGEN). Using the sdAb and through the current method utilizing biotinylated QDs and sdAb-RZ.
 extended histidine tail. The right side shows a QD capped with 80% DHLA-PEG550-
Z-biotin interaction. The structure of the sdAb is from PDB:4W70 [40] and the RZ
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16 C was performed overnight. Correct sequences were identiﬁed
by DNA sequencing (Euoﬁns Genomics).
2.3. Expression, production, and puriﬁcation of SdAb-RZ and RZh
proteins
Protein expression and puriﬁcation were performed similar to
methods described previously [7]. Brieﬂy, a single colony of
Rosetta (DE3) cells harboring the expression plasmid was used to
inoculate a 50 mL overnight culture grown at 30 C in Luria broth
(LB) in the presence of 100 mg/mL ampicillin and 35 mg/mL
chloramphenicol. The following day, a 500 mL culture in LB was
inoculated using the overnight culture and grown at 30 C for 3 h.
The temperature was then reduced to 25 C and protein expression
was induced with the addition of 0.5 mM IPTG (isopropyl
b-D-1-thiogalactopyranoside). After 3 h, protein was harvested
by osmotic shock. Brieﬂy, ﬁrst cell pellets from 500 mL of culture
were homogenized in 14 mL cold sucrose-tris (750 mM sucrose,
100 mM Tris pH 7.5). Next 28 mL of 1 mM ethylenediaminete-
traaceticacid (EDTA; pH 8) was added drop-by-drop to each sample
and the samples were shaken for 15 min on ice. Finally 1 mL of
500 mM MgCl2 was added, the samples were incubated a further
10 min and the cells were pelleted. 5 mL of 10  IMAC buffer (0.2 M
Na2HPO4, 4 M NaCl, 0.2 M imidazole, pH 7.5) and 0.5 mL of Ni
Separose (GE Healthcare) were added to the supernatant and the
sample tumbled overnight at 4 C on a rotisserie. Next, the resin
was washed with 1  IMAC buffer and eluted with IMAC buffer
containing 500 mM imidazole. Samples were puriﬁed by immo-
bilized metal afﬁnity chromatography (IMAC) and size-exclusion
chromatography using the BioLogic Duo-ﬂow chromatography
system (Bio-Rad, Hercules, CA) and either an ENrich SEC
70 10  300 mm column or a Superdex G75 10  300 mm column
(GE Healthcare, Piscataway, NJ) equilibrated in phosphate buffer
saline (PBS) +0.02% azide and run at 0.5 mL/min.
Yields of RZh from the periplasmic production were determined
to be 13.5  2.5 mg/L by measuring the absorbance at 280 nm using
a NanoDrop spectrophotometer. Previous reports detailed the
recombinant production of unfused RZ from the cytoplasm with an
average yield of 4 mg/L [13,14]. Thus, periplasmic production of the
RZh with the tag was signiﬁcantly improved from the previously
reported RZ production [13,14], even though production into the
periplasmic space is generally considered a limiting factor [34,35].
In part this may be due to improved recovery from the IMAC versus
the 2-iminobiotin column.
To evaluate the quaternary state (monomer, dimer, or tetramer)
of the fusion constructs, 0.5 mL samples of the proteins either with
or without excess biotin (20 mM) added were rerun on the ENrich
SEC 70 column (Fig. S1). Unexpectedly, size exclusion chromatog-
raphy of the IMAC puriﬁed RZh, in the absence of biotin eluted as a
tetramer. However, upon additional size exclusion separations of
dilutions of the RZh protein, a concentration dependent tetramer
to dimer transition was observed. In the presence of excess biotin
we observed that a concentration independent dimer form
predominated. On denaturing gels, following the standard protocol
to denature the protein ﬁrst, RZh ran as a 29.1 kDa dimer both in
the presence and absence of biotin, attesting to the high stability of
the dimer interaction (Fig. S2). In general, it appears that the biotin
bound form of RZh is not only more thermostable, but is also more
soluble as it was observed to consistently elute from the gel
ﬁltration column with a more narrow half-height bandwidth than
was observe for biotin free RZh (Fig. S1B and S1C). Perhaps the
biotin binding pocket shows some propensity to interact weakly
with the column matrix or weak tetramer to dimer transitions are
occurring.2.4. Biotin functionalized QDs
Luminescent CdSe-CdZnS-ZnS core-shell-shell quantum dots
were prepared as described previously [36]. The size of the
CdSe-CdZnS-ZnS core-shell-shell QDs utilized in this work was
4.6  0.44 nm as measured by transmission electron microscopy
(TEM); the QDs had an emission centered at 540 nm and were
capped with a combination of 80% DHLA-PEG550-OMe and 20%
DHLA-PEG400-biotin. There are about 100–200 ligands per QD and
thus there are estimated to be 20–40 biotins per QD [30].
The biotin-functionalized QDs (Bt-QDs), as well as DHLA-PEG
capped QDs with an emission at 540 nm, were diluted in PBS and
applied in triplicate at concentrations ranging from 100 nM down
to 0.8 nM (5-fold dilution series) to wells of a NeutrAvidin coated
96-well plate that had been washed three times with PBS
containing 0.05% tween (PBST). After incubating for 2 h the
photoluminescence (PL) was measured and then the QD solutions
were removed and wells were washed 3 times with PBS and ﬁnal
PL spectra were collected. The measurement taken before washing
the wells conﬁrmed that the spectra of the QD dilutions were as
expected; the measurement after washing the wells indicates how
the QDs bound to the plate. All ﬂuorescence emission spectra were
measured from each well using a Tecan Inﬁnite M1000. The
excitation wavelength was 300 nm. Data was collected every 5 nm
from 450 to 600 nm. Each QD sample was examined in triplicate.
2.5. Conjugation of sdAb-RZ to biotin functionalized QDs
Biotin functionalized QDs (200 pmol; 10 mL of a 19.8 mM
solution) and D12f-L10-RZ (4000 pM; 77 mL of a 52 mM solution)
were mixed, made up to 1 mL in PBS and incubated for
approximately a half hour on ice. This gave a molar ratio of
20:1 sdAb-RZ to QDs, a ratio chosen to saturate the QD surface. The
sdAb-RZ-QD mixture was applied to a ﬂoat-a-lyzer with a 100 kDa
cut off (Spectra/Por) and dialyzed against PBS with three buffer
changes with the ﬁnal dialysis overnight against fresh buffer. The
next day the sdAb-RZ-QDs were removed from the dialysis cup and
the cup was rinsed with 1 mL PBS to give a ﬁnal volume of 2 mL
with a concentration of 100 nM QD reagent, assuming no loss on
dialysis.
2.6. Binding determinations by surface plasmon resonance (SPR)
All SPR experiments were performed using a Bio-Rad ProteOn
XPR36 and the data were analyzed using the accompanying
ProteOn Manager 3.1software using a global analysis Langmuir ﬁt.
Raw data is shown for the immobilization steps, for the ricin
binding and subsequent ampliﬁcation with QDs. The data is
corrected for interspot signal and zero concentration, when
appropriate. For the evaluation of the QD bioconjugates three
different anti-ricin antibodies were utilized: D12f and H1W are
both sdAb developed by us [32], and mAb 5F4, which was the kind
gift of Dr. Thomas O’Brien, Tetracore (Rockville, MD). These three
antibodies all bind to different epitopes on the ricin A chain and
were immobilized using a concentration of 20 mg/mL onto a GLC
chip, which has a compact carboxyl modiﬁed polymer layer with a
binding capacity of approximately one protein monolayer, using
10 mM acetate buffer pH 5.0 by the standard EDC amine coupling
chemistry recommended by Bio-Rad. The immobilized antibodies
were then allowed to bind ricin for 120 s, 100 mL/min, at a range of
concentrations from 100 to 0 nM, then biotin capped QDs (Bt-QDs;
10 nM) that had been saturated with the D12f-L10-RZ fusion
(prepared as described above) were ﬂowed over the chip for 120 s,
followed by 240 s of buffer (PBS +0.005% Tween-20). Following
regeneration of the same chip with 0.085% phosphoric acid the
antibodies were allowed to bind 100 nM ricin on all lanes for 120 s.
Fig. 2. Demonstrating the effectiveness of rhizavidin (RZh) using HTE chip on the ProteOn SPR. Panel A shows the rhizavidin (20 mg/mL) binding to all 6 spots on one lane of
the HTE chip via the 6xHis tags. Panel B shows the same spots as in panel A being coated with a biotinylated anti-ricin sdAb, D12f (Bt-D12f). Panel C shows six spots from
another lane being coated with the D12f-L10-RZ via the His tags. After the sensor chip is rotated 90 , the ability of both lanes so prepared (panels B and C) to bind to ricin was
demonstrated as shown in panels D and E, for the Bt-D12f on the RZh alone and the D12-L10-RZ respectively.
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concentrations of 10, 3.3, 1.1, 0.37, 0.124, and 0 nM QD conjugates
were each ﬂowed over one lane for 120 s followed by 240 s of
buffer.
The RZh was tested on a Bio-Rad HTE sensor chip, which has a
high density of tris-NTA complexes for improved capturing of
histidine-tagged protein providing excellent binding stability and
regeneration capability in the capture of histidine-tagged proteins.
The HTE chip was ﬁrst exposed to 10 mM Ni sulfate for 300 s at
30 mL/min (not shown). Lanes 1–5 were then coated with RZh
(only 1 lane is shown, however similar results were obtained on all
ﬁve lane) or D12f-L10-RZ (only a single lane was used as a control)
via their 6xHis-tags by ﬂowing for 20 mg/mL of each over the
respective lane at 30 mL/min for 300 s. The RZh was then allowed tobind Bt-D12f (20 mg/mL) for 300 s. Afterwards the chip was turned
90 and lanes were challenged with a range of ricin concentrations
(100–0 nM) for 90 s at 100 mL/min, the off rate was followed for
600 s. While the HTE chip has less disassociation of the His-tagged
protein than Bio-Rad’s lower density HTG chips, as RZh is a dimer
and can bind with two His tails, its off rate is further suppressed. In
addition, the interspot correction capability of the ProteOn allows
for correction of background drift.
2.7. Experion automated electrophoresis system
To further evaluate the quaternary structure of the proteins and
their stability samples either native or denatured were analyzed on
the Bio-Rad Experion system following provided instructions, see
Fig. 3. Binding of QDs capped with DHLA PEG and 20% biotin reagent (Bt-QD), and QDs capped only with DHLA PEG to NeutrAvidin coated wells. The QD dilutions (100 nM,
20 nM, 4 nM and 0.8 nM) were ﬁrst applied to NeutrAvidin coated wells and allowed to bind, before the wells were washed and ﬂuorescence spectra were measured. Spectra
are color coded; the key on the right side of the plot indicates which colors and symbols correspond to which type of QD and which dilution. The inset on the left side of the
plot shows the values of the ﬂuorescence emission at 540 nm for both the Bt-QDs (green triangles) and the QDs capped only with DHLA PEG (red triangles) plotted against QD
concentration. Excitation was at 300 nm. This plot indicates that the Bt-QDs were speciﬁcally binding to the NeutrAvidin. Data points represent the average ﬂuorescence from
three wells; error bars are the standard deviation.
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examined in native and reduced conditions, both with and without
added biotin (20 mM). (Fig. S2).
2.8. SdAb-QD bioconjugate use in ﬂuoroimmunoassays
Fluoroimmunoassays were carried out similar to the previous
sdAb-QD assays [20]. Wells of a 96-well plate (Nunc, maxisorb)
were coated overnight at 4 C with capture antibody using the
monoclonal antibody 5F4 at a concentration of 3 mg/mL in PBS. The
remaining incubation steps were all carried out at room
temperature. The next morning, the coating liquid was dumped
out and the wells blocked for an hour with PBS containing 4%
powdered milk. Wells were washed two times with PBST and then
dilutions of ricin, made up in PBS containing 1 mg/mL BSA (PBS-B)
were applied to the wells (4-fold dilutions starting at 10 mg/mL).
After 1.5 h wells were washed with PBST. The sdAb-RZ-QD
reagent was diluted to 14 nM in PBS-B and 75 mL was added per
well and incubated for 1.5 h. The sdAb-RZ-QD solution was
removed and the wells washed with PBST. The plate was slapped
on paper towels to remove remaining wash buffer from wells and
ﬂuorescence at 545 nm was measured on a Tecan Inﬁnite
M1000 using an excitation of 300 nm. Measurements were done
in triplicate; controls in which there was no coating antibody, no
ricin, or no sdAb-RZ-QDs were also performed.
3. Results and discussion
3.1. Production of sdAb-RZ genetic fusion
Recently, we published the ﬁrst report of genetic fusions
between sdAbs and the biotin binding protein RZ [10]. In that work
we showed that the sdAb-RZ conjugates appeared to have the same
ability to provide oriented capture surfaces as we had found with
sdAb fusions to a streptavidin core [11], with the advantage of
20-fold better protein production of 14 mg/L of sdAb-RZ fusions.
All these constructs included a sequence from the natural llama
upper hinge linking the two proteins, and used a pECAN45-based
expression vector.
For the production of sdAbs, we have found our best protein
expression when the sdAb sequence was inserted into the pET22bexpression vector without including any sequence from the upper
hinge [37]. Thus, for second-generation sdAb-RZ reagents we
switched to the pET22b expression vector, and constructed a
version of the sdAb-RZ that replaced the upper hinge linker with a
more generic one that contained the amino acid sequence
comprising the restriction sites used in cloning and an additional
10 amino acid Gly-Ser linker (AAALEGGGGSGGGGS) between the
two domains. In addition, for this work we utilized the D12f ricin
binding sdAb which shows excellent afﬁnity with a high melting
temperature (78 C) to provide a reagent with improved rugged-
ness compared to the original RZ fusion with the anti-ricin C8 sdAb
that melts 60 C [32]. When puriﬁed the fusion protein, D12f-L10-
RZ, eluted from the ENrich SEC 70 as a 60 kDa dimer, with biotin
having no effect on the elution volume, indicating the fusion
construct always exists as a dimer (Fig. S1A). On the Experion,
D12f-L10-RZ ran as 63 kDa dimer when in the native state, but as
30.3 kDa monomer when denatured (Fig. S2).
3.2. Demonstration of the utility of unfused RZh
In addition to our prime objective, we also prepared and
evaluated the utility of the RZh protein by performing a test similar
to that described by Zhou et al. [38], see Fig. 2. The RZh and the
D12f-L10-RZ were both captured via their 6xHis tags onto the
surface of a HTE chip. RZh being a dimer, the two His tags form a
more stable interaction to the tris-NTA surface than monomeric
proteins with a single His tag. The RZh was then allowed to bind a
biotinylated D12f (Bt-D12f). After the capture reagents were
immobilized, the chip was turned 90 and various concentration of
ricin (100–0 nM) were then ﬂowed over the chip. The quantity of
ricin bound by the two surfaces was very comparable and the
afﬁnity observed was the same for both forms of D12f (KD = 86
 24 pM). The oriented RZh were calculated to bind 1.3 Bt-D12f
for each RZh dimer and the Bt-D12f bind 1 ricin for every 2 Bt-
D12f immobilized. Thus, an excellent level of binding activity was
obtained. These experiments show that RZh can be used in place of
the other His-tagged biotin binding proteins for a wide array of
applications, with the added advantage that RZh produced at least
a 10-fold better yield in E. coli than the strep-core biotin binding
protein (not shown).
Fig. 4. Effectiveness of Biotin—QDs coated with D12f-L10-RZ to function as an ampliﬁer in SPR sandwich assays. A GLC SPR chip was coated with anti-ricin binders [mAb-5F4
(top), D12f (middle), and H1W (bottom)]. The chip was turned 90 , and allowed to bind ricin for 120 s at a range of concentrations from 100 to 0 nM as indicated, left column.
The left side of the ﬁgure shows the binding of ricin dilutions to the three capture antibodies. Then sdAb-RZ-QD complexes at 10 nM were ﬂowed over the surfaces for 120 s
followed by buffer to monitor for dissociation as is shown on the right side of the ﬁgure. The sdAb-RZ-QD complexes bound rapidly in a ricin dose dependent manner.
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Functionality of the QDs capped with 20% biotinylated ligand
(Bt-QDs) was ﬁrst assessed by examining their ability to bind a
NeutrAvidin coated plate. Dilution series of QDs, with and without
biotin functionalized ligand, were applied to wells of a NeutrAvidinTable 1
Binding constants determined for the three capture antibodies and apparent values
determined for the D12f-RZ-QDs using (1) mAb 5F4 and (2&3) H1W as capture
molecule for ricin.
kaM1 s1 kd 1 s1 KDM
mAb 5F4 6.2  105 4.1 104 6.7  1010
D12f 6.6  105 4.3  105 6.5 1011
H1W 3.6  105 2.4 104 7.5 1010
1D12f-L10-RZ-QD 2.0  107 3.1 1018 6.7  1025
2D12f-L10-RZ-QD 1.0  107 2.3  1017 6.7  1024
3C8-QD 6.4 106 2.2  104 3.5 1011coated plate. The biotin-functionalized QDs showed binding to the
NeutrAvidin, in contrast similar QDs that were only coated with
DHLA-PEG-OMe showed only minimal non-speciﬁc binding to the
NeutrAvidin (Fig. 3). This experiment veriﬁed the availability of the
biotin on the QDs for binding to NeutrAvidin and indicated that the
Bt-QDs would speciﬁcally bind to NeutrAvidin.
3.4. Evaluation of sdAb-RZ-QDs by SPR
The Bt-QDs were conjugated to D12f-L10-RZ and their binding
to ricin evaluated by SPR to determine the binding kinetics of the
QD reagents and evaluate them for the detection of ricin.
Previously we had observed that sdAb coupled to DHLA capped
QDs through an extended His tail provided a >2-fold ampliﬁcation
over unconjugated sdAbs for the detection of ricin, while
commercial streptavidin functionalized QDs provided less of an
ampliﬁcation [20]. In this work the D12f-L10-RZ provided the
recognition element that was conjugated to the QDs. The high
Fig. 5. Evaluation of dose response of QD conjugates. A GLC SPR chip was coated with anti-ricin binders [mAb-5F4 (top), D12f (middle), and H1W (bottom)], the same as in
Fig. 5. Each lane was exposed to ricin 100 nM for 90 s (left column). As can be seen on the left side of the ﬁgure, for each of the three capture antibodies, this generated
approximately the same signal in each of the six lanes. Next the lanes were exposed to the SdAb-RZ-QD conjugates at range of dilutions, starting at 10 to 0 nM (as indicated in
the legend). Data is shown on the right side of the ﬁgure. A dose dependent on rate was observed, similar as one would see for any typical analyte.
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D12f on the Bt-QD surface. A schematic of two types of sdAb-QD
conjugates is shown in Fig. 1.
The sdAb-RZ-QDs were examined to determine their binding
kinetics and their ability to amplify signals in sandwich assays for
ricin. Ricin was bound by three different immobilized capture
antibodies: a monoclonal antibody (mAb 5F4), the D12f sdAb, and
the H1W sdAb that recognizes a different epitope on ricin than
D12f (Fig. 4 left panels) [32]. The sdAb-RZ-QDs were then applied
to the antibody-captured ricin (Fig. 4 right panels). Binding kinetics
for the capture reagents, as well as the sdAb-RZ-QDs are shown in
Table 1. The interaction of the D12f-L10-RZ-QD with ricin is
multivalent, and is reﬂected in the slow off rates which are beyond
the limit of our ability to accurately measure. When off rates
become very low the ability to differentiate becomes more
challenging as the value can easily be affected by drift. As
expected, no binding of the D12f-L10-RZ-QDs was recorded when
ricin was captured by the immobilized D12f. This is because ricin isa simple heterodimeric toxin without repeating epitopes. In order
to form a successful sandwich binding, reagents must recognize
different portions of the toxin.
An evaluation of the dose response of the D12f-L10-RZ-QD was
carried out, looking at the signal generated by dilutions of the
sdAb-RZ-QDs on a captured ricin surface. The three anti-ricin
antibodies (mAb 5F4, H1W and D12f) were exposed to 100 nM
ricin; the left panel of Fig. 5 shows that for each of the three capture
reagents, the signal generated by applying ricin was roughly
equivalent across the 6 lanes. Applying a dilution series of the
sdAb-RZ-QDs showed a dose-dependent on rate as is expected for a
typical analyte (Fig. 5 right side). As before no binding was
observed with the D12f capture reagent.
Fig. 6 shows the comparison of the DHLA capped QDs coated
with C8, a sdAb highly homologous to D12f, via its extended His-
tag and the sdAb-RZ-QD conjugates prepared for this work. The
SPR binding studies that utilize the sdAb-QDs enable us to compare
on rates; as this is a multi-valent system, the on rates are relative.
Fig. 6. Comparison of DHLA capped QDs prepared coated with the anti-ricin sdAb C8 via its His-tag (left panel) [20] with the current Bt-QDs conjugated with D12f-L10-RZ
(right panel). For both sets of data ricin at various concentration was captured via mAb 5F4 immobilized on the surface of the SPR sensor chip (top panels). The DHLA-QDs gave
an ampliﬁcation >3-fold ricin alone, however the Bt-QDs appear to have a superior on rate >2-fold.
J.L. Liu et al. / Biotechnology Reports 10 (2016) 56–65 63Our current QDs displayed faster on rate binding kinetics by
3.1 times than those used previously (Table 1); thus, at least 3 fold
lower concentrations of current QDs can be used. This is a useful
advantage when dealing with expensive reagents such QDs. Fig. 6
also shows a comparison of the ampliﬁcation observed, previously
greater than 2-fold was obtained versus the less than 1-fold
increase seen with our current QDs. It is unclear, why these QD
bioconjugates provide less ampliﬁcation, even though they appearFig. 7. Fluoroimmunoassay, utilizing sdAb-RZ-QD reagents for the detection of ricin. In th
ricin. Excess toxin was washed and then the sdAb-RZ-QD reagent allowed to bind to capt
545 nm (300 nm excitation). Dark brown circles represent signal generated by a sandwich
the absence of capture antibody and represent a combination of non-speciﬁc binding by b
given in nM; for reference 100 nM ricin 6 mg/mL. Each ricin concentration was assayed ijust as active as the previously utilized QDs. Previously we had also
observed less ampliﬁcation when examining sdAb-QD conjugates
prepared utilizing commercial streptavidin coated QDs [20];
potentially the ligands used to make the QDs biocompatible are
a factor in ampliﬁcation. While the greater thickness of Bt-PEG
layer on the QDs, as well as the increased thickness of the sdAb-RZ
conjugate, increase the distance of the QDs from the surface,
additional experimentation is required to determine if this changeese assays, a capture antibody was adsorbed onto wells and exposed to dilutions of
ured ricin. Finally wells were washed and ﬂuorescence measured from each well at
 assay with capture monoclonal antibody 5F4. Light brown triangles are the signal in
oth the ricin antigen and the ﬂuorescent sdAb-RZ-QD tracer. Ricin concentrations are
n triplicate, the average value is plotted; error bars represent the standard deviation.
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QDs bound with high speciﬁcity, as no binding to ricin that had
been captured using covalently immobilized D12f-sdAb was
observed. SPR testing of QD bioconjugates, however, was
envisioned more as a means to evaluate the nature of the QD
bioconjugates rather than as a method for SPR ampliﬁcation.
Alternatives such as gold nanoparticles are likely superior for that
application [39].
3.5. Fluroimmunoassays utilizing sdAb-RZ-QDs
We had previously shown that sdAbs directionally conjugated
to DHLA-capped CdSe–ZnS core–shell QDs could be successfully
utilized in ﬂuoroimmunoassays for the detection of ricin [20].
Fig. 7 shows a ﬂuoroimmunoassay utilizing the sdAb-RZ-QD
reagent for ricin detection. Examination of binding to wells that
had no capture antibody show non-speciﬁc binding only at the
highest ricin concentration; this signal is likely due to non-speciﬁc
binding of the ricin toxin, as there was no binding of the sdAb-RZ-
QD reagent to similar wells having lower amounts of ricin. Using
the sdAb-RZ-QD reporter reagent, detection of ricin was essentially
identical to what we had observed previously using sdAbs
conjugated to QDs through an extended His tail as the reporter
and the same monoclonal antibody as a capture [20]. In both cases
we demonstrated detection of toxin down to 0.16 nM
(10 ng/mL). These sdAb-RZ reagents should enable oriented
immobilization on any biotinylated surface, including commercial
preparations of biotinylated QDs.
4. Conclusions
This work detailed the production and characterization of sdAb-
RZ fusions with a generic Gly-Ser linker in place of the hinge region
as well as RZh (RZ with a His tag). The proteins produced well (at
least 10 mg/L), and were fully functional, with both the RZ portion
showing binding to biotin, and the sdAb portion of the fusions
recognizing ricin. The focus however was demonstrating the
bioconjugation of sdAb-RZ to Bt QDs. The antigen recognition
function was provided by a previously described high-afﬁnity ricin
binding sdAb. The advantages of QD bioconjugation using a sdAb-
RZ fusion include the ability to prepare a wide range of sdAb-RZ
fusions that can be conjugated to stable bio-compatible biotin
coated QDs as desired. The dimeric nature of RZ makes the
attachment bivalent and thus makes for an extremely stable
noncolavent interaction. Just as important, the sdAb-RZ coats the
BT-QDs in an oriented manner, providing a highly active surface. As
the RZ monomer is of similar size as an sdAb molecule, they pack
efﬁciently onto the surface of the QD. This format provides a useful
alternative to preparation of streptavidin-QDs that are coated with
biotin tagged ligands. The use of sdAb-RZ to bioconjuagate QDs or
any biotinylated nano or microparticle hold great promise as
diagnostic and imaging reagents as well as for detection
applications.
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